<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 332 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page331.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=332">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 332 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 332</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=332"><img src="../thumb/332.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>Endocrine System - 19.1.2.1 / 19.1.2.2                                         2020-04 / 295








       Contraindications: Hepat.impairm.incl.pre-treatm. ALT or AST   (S3) TABS, 42/21.2/1089, 1090, 1091  ONGLYZA, AstraZeneca [P/S] &
       &gt;2,5x upper limit of norm.    717788-001: 50/500 mg, 56, R333,15  Saxagliptin HCl
       Side effects: Angioed., hepat.dysfunct., trem., dizzin., headache,   717790-001: 50/850 mg, 56, R333,15  Indications: Adjunct to diet & exerc.in adults with type 2 diabet.
       asthen., periph.oed., naus., flatul., GORD, diarrh., constip., decr.bld.  717791-001: 50/1 000 mg, 56, R333,15  either as monother./in combin. with metformin/ a thiazolinedione/a
       gluc., hypoglycaem., hepatit. revers. with discont., urticar., pancreatit.  Dosage: Indiv.accord.to current regim./effic./ tolerabil.not exceed.   sulfonylur./ insul. (with or without metformin) when sngl.agent alone,
       Warnings and special precautions: LFT’s prior to init.treatm.&   max.recomm.dly.dos.of sitagliptin 100 mg. Admin. 2x/day with meals.  with diet & exerc.does not prov.adeq. glycaem. contr.
                st
       imperat.mnthly for 1  6 mnths.& then 3 mnthly., discont. if AST/ALT   Switch.from co-admin.of sitagliptin & metformin: Bas.start.dos.  (S3) TABS. 43/21.2/0608, 0609
       incr.of 3xULN, discont. & do not reinit.if jaund./other sympts. suggest.   on current sitagliptin & metformin dos.  716640-001: 2,5 mg, 30, R175,09
       of liv.dysfunct.dev., safety in pregn.& lactat. not est., ren.impairm.,   Pts.inadeq. contr.on dual combin.ther.with any 2 of the foll.3   716641-001: 5 mg, 30, R175,09
       not recomm.in pts. und. 18 yrs.as not stud., not a substit. for insul.in   agents (sitagliptin, metformin or a sulphonylurea): Usual   Dosage: Monother.& add-on combinat.ther: Recomm.dos: 5 mg
       insul. req.pts., not for use in type 1 diab., diabet. ketoacidos., lact.intol.  start.dos. of Janumet should prov.sitaglipt.50 mg 2x/day. Cons.  once dly as monother.or in combin. with metformin/a thiazolidinedi-
                                     pt.glycaem.contr.lev.& current metformin dos. when determin.met-  one/ a sulfonylurea/insul.(with or without metformin)
       JALRAMET, Novartis [P/S]      form.start.dos. Pts.current. on/ init.a sulphonylurea.may requir.low.   Contraindications: Sev.hepat.impairm., pancreatit. hist., type 1
       Vildagliptin 50 mg, metformin HCl 850 mg  sulphonylurea dos.  diab., treatm.of diabet. ketoacidos, DPP4 inhibit. hypersens., safety
       Vildagliptin 50 mg, metformin HCl 1 000 mg  Contraindications: Ren.dis./ dysfunct.with ser. creatin.lev.&gt;   in pregn./ lactat./paed.& adolesc.pts.not est., lact. intol.
       Indications: Diet.& exerc.adjunct. in type 2 diab. mellit.pts.  133 micromol/L (males) & &gt;124 micromol /L (fem), abnorm.creatin.  Side effects: URTI, UTI, sinusit., GI disturbs., headache, hypogly-
       who are already stabilis.with separate vildagliptin & metformin   clear. result.from CV collapse/ac.MI/septicaem., ac./ chron.metabol.  caem., periph.oed.with combin.ther., hypersens.reacts.incl.anaphy-
       combinat.at same dos., add-on to insul.as adjunct to diet &exerc.   acidos.incl.diab.ketoacidos.with/ without coma, sev.hypersens.react.  lax./ angio-oed./rash & urticar., ac.pancreatit.
       in pts. on stable dos.of insulin plus separate vildagliptin & met-  hist., safety in pregn.not est., lactat., safety & effic.not est.in childr.   Warnings and special precautions: Ren.funct. assessm. bef. init.
       formin combinat.at same dos., in combinat. with a sulphonylu-  und.18 yrs., not for use in type 1 diab./diab. ketoacidos.treatm.,   ther.& period.theraft., mod.to sev.ren. funct. impairm., end-stage ren.
       rea (i.e. triple combinat. ther.) as adjunct to diet & exerc. in pts.  discont.temp.in pts. undergo. radiolog.stud.involv.iodinat.contrast   dis., cross. placenta & secret.in breast milk of rats, low. sulfonylur.dos.
       stabilis. on a separate vildagliptin, metformin and sulphonylurea   mater. intravasc. admin.& only re-instit.aft.norm. ren. funct. determ.  reqd.to reduc.hypoglycaem.risk. when used in combin.ther., discont.
       combinat.at same dos.         Side-effects: Ac.pancreatit.incl.fat./non-fatal haemorrh./ necro-  if ser. hypersens. reacts./pancreatit.suspect.
       (S3) TABS, 48/21.2/0729, 0730  tis.pancreatit., ser.hypersens. reacts.incl.anaphylax./angioed., mild   Drug interactions: Poss.decr.plasma conc.with CYP3A4/5 induc.
       3000953-001: 50/850 mg, 30, R113,79  erythema, skin reacts.incl. Stev.Johnson syndr., somnol., diarrh.,   (eg.carbamazepine/ dexamethasone/ phenobarbital/phenytoin/
       3000953-002: 50/850 mg, 60, R227,59  hypoglycaem., decr.bld.gluc., headache, dizzin., constip., loss of ap-  rifampicin).
       3000955-001: 50/1 000 mg, 30, R113,79  pet., URTI, nasopharyngit., osteoarthrit., pain in extremit./ abdom.,   See also MDR page 230.
       3000955-002: 50/1 000 mg, 60, R227,59  worsen.ren.funct.incl.ac.ren.fail., N&V, decr.Vit.B12 & folic acid ab-
       Dosage: Do not exceed max.dly.dos.of 100 mg vildagliptin  Ad-  sorpt., lact.acidos., metall.taste.
       min.with meals.               Special precautions: Ac.pancreatit./lact.acidos. sympt., discont.
       Recomm.start.dos: Bas.on pts.current vildagliptin and/or met-  Janumet & all potent. suspect meds.immed.if pancreatit.suspect.,  19.1.2.2  SGLT2 inhibitors
       formin regimen.               monit.ren. funct. bef.init.ther.& at least annual.thereaft., elderly,
       In combinat.with sulphonylurea/insulin: Dos. should prov.vilda-  discont.ther.in case of ren.funct.impairm., concom.digoxin, excess.  FORXIGA (MDR Listing)
       gliptin dos.as 50 mg 2xdly. (100 mg tot.dly.dos) & a dos.of metform.  alcoh.intake, avoid in hepat.dis., suspend.treatm.for surg.proced.  JARDIANCE (MDR Listing)
       simil.to dos. already being taken.  where fluid & food restrict., annual haematolog.monit.& Vit.B12   FORXIGA, AstraZeneca &
       Contraindications: Ren.dis./dysfunct.with ser. creatin. lev.&gt;1,5 mg/  measurem., eval.for ketoacidos.&/lact. acidos.if clinic.status of prev.  Dapagliflozin
       dl (males)& &gt;1,4 mg/dl (fem.), hepat. impairm.incl.pre-treatm.ALTor   contr.type 2 diab.pts. chang., condits.where bld.gluc.contr.temporar.   Indications: Improv.glycaem.contr.in adults(18 yrs & old.) with type 2
       AST &gt;2,5x ULN., CHF req.pharmacol.treatm., ac./chron. metabol.   lost, concom.meds.affect.ren.funct./have signific. haemodynam.  diabet.mellit.as monother. adjunct to diet & exerc./add-on combinat.
       acidos.incl.diabet.ketoacidos., tempor. discont.in radiolog.stud.involv.  changes/interfer with metform. disposit., concom.meds.lead.to loss   ther.with gluc.-lower. meds. when these togeth.with diet & exerc.do
       intravasc.iodinat. contrast med.  of glycaem. contr., ac./unstab.CHF/ac.MI/other condits. charact-  not prov.adeq.glycaem.contr.
       Side effects: V.common: N&V, diarrh., abdom. pain, appet.loss.   eris. by hypoxaem.& metform.accumulat. hav.been assoc.with lact.  (S4) TABS, 46/21.2/0214, 0215
       Common: Trem., dizzin., headache, chills, naus., GORD, hypogly-  acidos., low.effect. metform. dos.to minim.lact.acidos.risk, suspend   723708-001: 5 mg, 30, R383,02
       caem., asthen., hyperhidros., metal.taste, Uncommon: Flatul.,   metform.in dehydrat./sepsis, incr.sulphonylurea induc.hypoglycaem.  723709-001: 10 mg, 30, R383,02
       constipat., periph.oed. V.rare: Decr.vit.B12 absorpt., lactic acidos.,   when used in combinat.with sitagliptin & metform., use in combi-  Dosage: Monother./add-on combinat.ther: Recom.dos: 10 mg
       abnorm.LFT, skin reacts.eg. erythema/prurit./urticar. Post market:   nat.with insul. not stud.  once dly. For pts.at risk of vol. deplet.due to co-exist.condits./concom.
       Pancreatit., hepatit., arthralg.somet.sev.  Drug interactions: Slight digoxin AUC incr., pharmacokinet.paramet.  meds. a 5 mg start.dos.may be appropr.
       Warnings and special precautions: Not a substit. for insul.in   of both compounds aff. with concom.furosemide, nifedipine enhanc.   Contraindications: Mod.to sev.ren.impairm. (GFR &lt; 60 ml/min)/
       insul.req.pts. not for use in type 1 diab./diabet.ketoacidos., monit.  metform.absorpt., alcoh.potent.metformin eff.on lact.ate metabol.,   end stage ren.fail./dialys., diabet. mellit. type 1, not indicat.for use
       ren.funct.& discont. if ren.impairm.pres., discont.& hospitalise if   metform.potential interact.with cation. meds., cert.meds.produc.  in weight contr. programmes, pregn.& lactat.
       metabol.acidos.suspect., excess.alcoh.as alcoh. potent. metformin   hyperglycaem. poss. lead to loss of glycaem.contr.  Side effects: Vulvovaginit., balanit., genit. infects., UTI incl. pyelo-
       eff., tempor.discont.with radiolog. stud.involv.IV admin.of iodinat.  nephrit./cystit., vulvovagin. prurit., hypo-glycaem.(with SU/insul.), vol.
       contrast media & only re-instit.aft.norm.ren.funct.determ., LFT’s   JANUVIA, MSD [P/S]  deplet., dehydrat, hypovolaem., hypotens., orthostat. hypotens., thirst,
       prior to init.treatm.& dur.treatm.at 3-mnthly. interv. dur.1  yr.& pe-  Sitagliptin phosph.  GI disords., rash, hyperhidros., back pain, glucosur., dysur., polyur.,
                               st
       riodic.thereaft., discont.if AST/ ALT incr.of 3x ULN persist, discont.  Indications: Diet.& exerc.adjunct.to improve glycaem. contr.in   noctur., dyslipidaem., incr.haematocrit./bld.creatin./bld. urea/ mean
       if jaund./ other signs of liv.dysfunct.devel.& do not reinit., NYHA   adults with type 2 diab.mellit.as monother., combinat.ther.with   ser.phosphor.lev., headache, nasopharyngit., bone fract., abnorm.LFT.
       class III HF & not recomm.in NYHA class IV HF as no exper., elderly   metform./a PPARg agonist when diet/exerc.& sngl.agent do not   Warnings and special precautions: Treatm.of diabet. ketoacidos.,
       & reduc.ren.funct.with reg. ren. funct.monit., lactic acidos.risk fact.,   prov. adeq.glycaem.contr.  ketoacidos.predispos.factors incl.low beta-cell funct.reserve result.
       condits. where ren.funct.may become imp., concom.meds. that affect   (S3) TABS, 41/21.2/0354, 0355, 0356  from pancreat. disords., e.g. pancreatit.hist./pancreat. surg., safety
       ren.funct./affect metform.disposit.eg cationic meds., shock/ac.CHF/  717785-001: 25 mg, 28, R333,15  & effic.not est.in paed.pts./pts.with recent (&lt;2 mnths.) CV event/NY
       ac.MI & condits. characteris. by hypoxaem.have been assoc.with   717786-001: 50 mg, 28, R333,15  Heart Assoc. class IV HF, discont.in case of suspect.metabol.acidos.&
       lact. acidos./preren.uraem., suspend.treatm.for surg. proced. where   717787-001: 100 mg, 28, R333,15  eval./ manag.accord., assess pts.pres.with S&S consist. with me-
       food & fluid restrict., annual haematol. monit. & Vit.B12 measurem.,   Dosage: Recomm.dos: 100 mg once dly in combinat. with   tabol.acidos.incl.N&V/abdom. pain/ malaise/shortn.of breath even
       eval.for ketoacidos. &/lact.acidos.if clinic.status of prev.control.type   metform./a PPARg agonist.  if bld.gluc. lev. &lt;11 mmol/l, metabol.acidos.predispos.fact., dapagli-
       2 diab.pts.change, condits.where suscept.to hypoglycaem.effs./bld.  If dos.miss.take when pt.remembers. Doubl.dos. not to be taken   flozin may decr.systol.& diastol.BP, monit. ren.funct. prior to init.&
       gluc.control tempor.lost eg stress./fev./trauma/surg.etc., monit.for   on one day.  periodic.thereaft., pts.at risk of vol.deplet.due to co-exist.condits./
       skin disords.eg blister./ulcerat., warn pt. of pancreatit.sympts.& if   Mod.ren.insuffic: 50 mg once dly.decr.if CrCl decr. to &lt;30 ml/min.  concom. meds.incl.loop diurets., discont.permanent.if.vol. deplet.
       suspect.discont.not reinit. if confirm., assess.S/E regard.ability to   Sev.ren.insuffic./end stage ren.dis.req. haemodialys: 25 mg   devel., eval.for UTI S&S, consid.temp. interrupt. when treat.pyelo-
       drive/operat.machin., safety in pregn.& lactat.not est., safety & ef-  once dly.without regard.to dialys.timing.  nephrit./urosepsis, a low. insul./insul.secretagog.dos.poss.reqd.to
       fic.not est. in pts.und.18 yrs.  Contraindications: Ser.hypersens.react.hist.to other DPP-4, not   reduce hypoglycaem.risk when used concom., glycaem. control moni-
       Interactions: Alcoh.intoxicat.incr.lact.acidos. risk., incr.angioed.  stud.in sev.hepat.insuffic., not recomm.in pregn./paed.pts., lactat.,   tor.with 1,5-AG assay unreliab. & use of altern.meth.recom., lact.intol.
       risk with ACE inhibit., furosemide incr.C max & bld.AUC of metform.,   not for use in type 1 diab.or diab.ketoacidos.treatm.  Drug interactions: Metabol.of dapagliflozin poss. decr. with con-
       metform. decr. C max & bld.AUC of furosemide, nifedipine incr.met-  Side effects: Ac.pancreatit.incl.fatal/non-fatal haemorrh./ necro-  com.ketoconazole, decr.system. expos. with concom.rifampicin.
       form.absorpt./C max/ AUC & excret. in urine, cimetidine incr.metform.  tis.pancreatit., decr.bld.gluc., somnol., GI disturbs., hypoglycaem.,   See also MDR page 224.
       plasma/ bld. conc.& AUC, meds.produc.hyperglycaem.may lead to   periph.oed., URTI, nasopharyngit., osteoarthrit., pain in extremit. /
       loss of glycaem.contr.        upp.abdom., hypersens.reacts.incl. anaphylax., exfoliat.skin con-  JARDIANCE, Ing.Pharm &
                                     dits.incl.Stev.-Johns. syndr., worsen.ren.funct.incl.ac.ren.fail.som-  Empagliflozin.
       JANUMET, MSD [P/S]            et. requir.dialys.           Indications: Adjunct to diet & exerc.to improv. glycaem. contr.in
       Sitagliptin 50(50, 50) mg, metformin HCl 500(850, 1 000) mg  Special precautions: Ac.pancreatit.sympt.& ther. discont.immed.  adults with type 2 diabet.mellit. Add-on combinat.ther: metformin/a
       Indications: Diet.& exerc.adjunct. in type 2 diab.mellit.pts. who   if pancreatit.suspect., secret. in milk of lactat.rats, mod.or sev.ren.  thiazolidinedione/ sulphonylurea/DPP4 inhibit./ insul. when these
       are already stabilis.with separate sitaglipt.& metformin combinat.at   insuffic., discont. ther.if hypersens.react.susp.& start altern. class   togeth.with diet & exerc.do not prov. adeq.glycaem.contr.
       same dos., diet & exerc.adjunct.in combin.with a sulphonylur. in type   meds.for diab., concom.digoxin, concom. meds. known to cause   (S4) TABS, 48/21.2/1380, 0411
       2 diab.mellit.inadeq.contr. with any 2 of the 3 agents of metformin/  hypoglycaem.e.g. sulphonylur. /insulin.  720929-001: 10 mg, 30, R508,99
       sitagliptin or a sulphonylur.  Drug interactions: Slight digoxin AUC incr.& peak meds.conc.  721619-001: 25 mg, 30, R508,99
                            S4 JARDIANCE ®  10 mg: Each film-coated tablet contains empagliflozin 10 mg. Reg. No. 48/21.2/1380. S4 JARDIANCE ®  25 mg: Each film-coated tablet contains empagliflozin 25 mg.
                            Reg. No. 48/21.2/0411. For full prescribing information refer to the professional information approved by the Regulatory Authority. Applicant details: Ingelheim Pharmaceuticals (Pty) Ltd,
                            407 Pine Ave, Randburg. Tel: +27 (011) 348-2400. Cpy. Reg. No. 1966/008618/07. BI Ref. No. PC-ZA-100408. Expiry date: August 2021.</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page331.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page327.html">327</a>&nbsp;&nbsp;&nbsp;<a href="page328.html">328</a>&nbsp;&nbsp;&nbsp;<a href="page329.html">329</a>&nbsp;&nbsp;&nbsp;<a href="page330.html">330</a>&nbsp;&nbsp;&nbsp;<a href="page331.html">331</a>&nbsp;&nbsp;&nbsp;<a href="page332.html">332</a>&nbsp;&nbsp;&nbsp;<a href="page333.html">333</a>&nbsp;&nbsp;&nbsp;<a href="page334.html">334</a>&nbsp;&nbsp;&nbsp;<a href="page335.html">335</a>&nbsp;&nbsp;&nbsp;<a href="page336.html">336</a>&nbsp;&nbsp;&nbsp;<a href="page337.html">337</a>
             </td>
             <td width="35%"><a href="page333.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page333.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
